Education
About Us
Working with TipRanks
Follow Us
Solasia Pharma KK (DE:9SO)
FRANKFURT:9SO
9SO Stock Chart & Stats
€0.14
<€0.01(2.88%)
At close: 4:00 PM EST
€0.14
<€0.01(2.88%)
Day’s Range― - ―
52-Week Range€0.13 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€47.41M
Enterprise Value€6.20B
Total Cash (Recent Filing)€1.83B
Total Debt (Recent Filing)€104.00M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Feb 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,209,000
10 Day Avg. Volume107
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)6.18
Price to Sales (P/S)22.63
P/FCF Ratio-6.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Solasia Pharma KK News
9SO FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was €0.13 and its highest was €0.24 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is €47.41M.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Feb 13, 2026 which is yesterday.
How were Solasia Pharma KK’s earnings last quarter?
Currently, no data Available
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 269,209,000 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in DE:9SO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Medrx Co., Ltd.
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―
Options Prices
Currently, No data available
---